Name (Synonyms) | Correlation | |
---|---|---|
drug2425 | TDR Wiki | 0.30 |
drug579 | Clevudine Wiki | 0.30 |
drug587 | Clofazimine Wiki | 0.30 |
drug1222 | Interferon beta-1b Wiki | 0.30 |
drug513 | Camostat Mesylate Wiki | 0.30 |
drug1231 | Intermediate dose thromboprophylaxis Wiki | 0.30 |
drug2515 | Thrombomodulin Modified Thrombin Generation Assay (TGA-TM) Wiki | 0.30 |
drug1005 | Graded exercise test Wiki | 0.30 |
drug581 | Clinical assessment Wiki | 0.30 |
drug2473 | Test PCR Wiki | 0.30 |
drug936 | Fibrin generation markers assays Wiki | 0.30 |
drug2434 | TRV027 Wiki | 0.30 |
drug1913 | Problem-solving and relationship improvement intervention. Wiki | 0.30 |
drug2486 | The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki | 0.30 |
drug590 | Cloth Face Mask Wiki | 0.30 |
drug2496 | Therapeutic Anticoagulation Wiki | 0.30 |
drug2514 | Thrombin generation test assay Wiki | 0.30 |
drug598 | Cognitive and behavioral intervention. Wiki | 0.30 |
drug592 | Co-mestring (co-coping) Wiki | 0.30 |
drug580 | Clinical Examination Wiki | 0.30 |
drug3003 | sodium chloride 0.9% Wiki | 0.30 |
drug2325 | Standard of Care thromboprophylaxis Wiki | 0.30 |
drug591 | Clungene rapid test cassette Wiki | 0.30 |
drug1539 | N-95 Respirator Wiki | 0.30 |
drug1974 | Quantra System Wiki | 0.30 |
drug2513 | Thrombin Generation Assay (TGA) Wiki | 0.30 |
drug1488 | Microcrystalline Cellulose, NF Wiki | 0.30 |
drug576 | Clazakizumab Wiki | 0.27 |
drug2499 | Therapeutic anticoagulation Wiki | 0.21 |
drug2187 | Saliva collection Wiki | 0.13 |
drug1645 | Normal saline Wiki | 0.13 |
drug315 | Baricitinib Wiki | 0.11 |
drug852 | Enoxaparin Wiki | 0.10 |
drug1822 | Placebo Wiki | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
D020141 | Hemostatic Disorders NIH | 1.00 |
D004211 | Disseminated Intravascular Coagulation NIH | 0.45 |
D001997 | Bronchopulmonary Dysplasia NIH | 0.30 |
D008595 | Menorrhagia NIH | 0.30 |
D006929 | Hyperaldosteronism NIH | 0.30 |
D014552 | Urinary Tract Infections NIH | 0.30 |
D054559 | Hyperphosphatemia NIH | 0.30 |
D004314 | Down Syndrome NIH | 0.30 |
D000309 | Adrenal Insufficiency NIH | 0.30 |
D007008 | Hypokalemia NIH | 0.30 |
D009080 | Mucocutaneous Lymph Node Syndrome NIH | 0.21 |
D006470 | Hemorrhage NIH | 0.21 |
D001289 | Attention Deficit Disorder with Hyperactivity NIH | 0.15 |
D012769 | Shock, NIH | 0.12 |
D054556 | Venous Thromboembolism NIH | 0.11 |
D006973 | Hypertension NIH | 0.08 |
D013923 | Thromboembolism NIH | 0.08 |
D004194 | Disease NIH | 0.05 |
D016638 | Critical Illness NIH | 0.04 |
D011024 | Pneumonia, Viral NIH | 0.04 |
D014777 | Virus Diseases NIH | 0.04 |
D007239 | Infection NIH | 0.03 |
D013577 | Syndrome NIH | 0.03 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.03 |
D003141 | Communicable Diseases NIH | 0.03 |
D018352 | Coronavirus Infections NIH | 0.02 |
D011014 | Pneumonia NIH | 0.02 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001928 | Abnormality of coagulation HPO | 1.00 |
HP:0005521 | Disseminated intravascular coagulation HPO | 0.45 |
HP:0002905 | Hyperphosphatemia HPO | 0.30 |
HP:0002900 | Hypokalemia HPO | 0.30 |
HP:0000846 | Adrenal insufficiency HPO | 0.30 |
HP:0000132 | Menorrhagia HPO | 0.30 |
HP:0000859 | Hyperaldosteronism HPO | 0.30 |
HP:0007018 | Attention deficit hyperactivity disorder HPO | 0.15 |
HP:0000822 | Hypertension HPO | 0.08 |
HP:0001907 | Thromboembolism HPO | 0.07 |
HP:0002090 | Pneumonia HPO | 0.02 |
There are 11 clinical trials
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Inflammation and abnormalities in laboratory coagulation tests are inseparably tied. For example, coagulation abnormalities are nearly universal in septic patients. Coagulation disorders have also been reported in many patients with severe courses of Coronavirus disease 2019 (Covid-19). But it is difficult to assess these changes. Global coagulation tests have been shown to incorrectly assess in vivo coagulation in patients admitted to intensive care units. But other tests are available. Thrombin generation assay (TGA) is a laboratory test which allows the assessment of an individual's potential to generate thrombin. But also in conventional TGA the protein C system is hardly activated because of the absence of endothelial cells (containing natural thrombomodulin) in the plasma sample. Therefore the investigators add recombinant human thrombomodulin to a conventional TGA. Thereby the investigators hope to be able to depict in vivo coagulation more closely than global coagulation tests do.
Description: nM;
Measure: ETP (AUC) without rhThrombomodulin (rhTM) Time: 6 monthsDescription: nM;
Measure: ETP (AUC) with rhThrombomodulin (rhTM) Time: 6 monthsDescription: Ratio of endogenous thrombin potential (ETP) with rhTM to ETP without rhTM
Measure: ETP-ratio Time: 6 monthsDescription: Comparison of ETP-ratios from ICU patients and ETP-ratios from citrated plasma samples from healthy donors
Measure: ETP-Normalisation Time: 6 monthsIncreased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death. Understanding this acquired coagulopathy is a prerequisite before specific interventional studies. The study investigators aim to apply a normalized and automated thrombin generation test (TGT), developed for testing the thrombotic risk (triggered by 5 pM Tissue Factor, with a purified thrombomodulin (TM) challenge) and to study its association with survival.
Description: Death yes/no during hopstilization, 28 days after admittence
Measure: 28-day survival rate Time: 1 monthDescription: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test latent period Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test latent period compared to reference plasma Time: Day 0Description: nmol/s; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test initial velocity Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test initial velocity compared to reference plasma Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test peak thrombin compared to reference plasma Time: Day 0Description: nmol/L; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test peak thrombin Time: Day 0Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test peak thrombin time Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test peak thrombin time compared to reference plasma Time: Day 0Description: seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test total thrombin generation time Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test total thrombin generation time compared to reference plasma Time: Day 0Description: Seconds; without (TM-) and with (TM+) purified thrombomodulin
Measure: Absolute thrombin generation test endogenous thrombin potential Time: Day 0Description: %; without (TM-) and with (TM+) purified thrombomodulin
Measure: Relative thrombin generation test endogenous thrombin potential compared to reference plasma Time: Day 0Description: Death yes/no
Measure: 3-month survival rate Time: 3 monthsDescription: Yes/no
Measure: Transfer to intensive care unit during hospitalization Time: 3 monthsDescription: Yes/no (deep vein thrombosis, pulmonary embolism, atherothrombosis flare, arterial thrombosis)
Measure: Thrombotic complication during hospitalization Time: 3 monthsDescription: µg / L, assayed by automated enzyme linked fluorescent assay (Vidas® D-dimers Exclusion ™ II)
Measure: Plasma concentrations of D-dimers Time: Day 0Description: mg / L, measured by automated immunoagglutination (STA®-Liatest® FM)
Measure: Plasma concentrations of soluble fibrin monomers Time: Day 0This prospective, randomized, open-label, multi-center interventional study is designed to compare the safety and efficacy of two LMWH dosing protocols in patients admitted to the University of Iowa Hospitals with COVID-19 who meet the modified ISTH Overt DIC criteria score ≥3. Patients will be randomized to standard prophylactic dose LMWH (standard of care arm) or intermediate-dose LMWH (intervention arm).
Description: Risk of all-cause mortality
Measure: Mortality Time: 30 Days post interventionDescription: Risk of ISTH defined major bleeding
Measure: Major Bleeding Time: 30 Days post interventionDescription: Risk of ischemic stroke, myocardial infarction and/or limb ischemia
Measure: Arterial Thrombosis Time: 30 Days post interventionDescription: Risk of symptomatic venous thromboembolism
Measure: Venous Thromboembolism Time: 30 Days post interventionDescription: duration of intensive care measures
Measure: ICU admission, intubation/ventilation Time: 30 Days post interventionDescription: The number of units of packed red blood cells transfused
Measure: Packed Red Blood Cell Transfusions Time: 30 Days post interventionDescription: The number of units of platelets transfused
Measure: Platelet Transfusions Time: 30 Days post interventionDescription: The number of units of Fresh Frozen Plasma Transfused
Measure: Fresh Frozen Plasma Transfusions Time: 30 Days post interventionDescription: The number of units of Cryoprecipitate Transfused
Measure: Cryoprecipitate Transfusions Time: 30 Days post interventionDescription: The number of units of Prothrombin Complex ConcentrateTransfused
Measure: Prothrombin Complex Concentrate Transfusions Time: 30 Days post interventionDescription: Will be performed in stored plasma using Calibrated Automated Thrombogram. The endogenous thrombin potential will be calculated in units of nM.Min.
Measure: The endogenous thrombin potential will be determined within 24 hours of randomization and weekly for 30 days or until hospital discharge Time: 30 days post interventionDescription: These assays will be performed in stored plasma. Quantification of cfDNA will be performed using Qubit dsDNA HS Assay kit. Histones H4, citrullinated-histone and DNA-myeloperoxidase will be measured using commercially available ELISA kit.
Measure: Plasma levels of cell-free DNA will be determined within 24 hours of randomization and weekly for 30 days or until hospital discharge Time: 30 days post interventionDescription: will be measured in stored plasma using a commercially available ELISA kit.
Measure: PAI-1 Time: 30 days post interventionCoagulopathy of COVID-19 afflicts approximately 20% of patients with severe COVID-19 and is associated with need for critical care and death. COVID-19 coagulopathy is characterized by elevated D-dimer, an indicator of fibrin formation and clot lysis, and a mildly prolonged prothrombin time, suggestive of coagulation consumption. To date, it seems that COVID-19 coagulopathy manifests with thromboembolism, thus anticoagulation may be of benefit. We propose to conduct a parallel pragmatic multi-centre open-label randomized controlled trial to determine the effect of therapeutic anticoagulation compared to standard care in hospitalized patients with COVID-19 and an elevated D-dimer (≥2X upper limit of normal {ULN}).
Description: Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.
Measure: Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days. Time: Up to 28 daysDescription: All-cause death
Measure: All-cause death Time: Up to 28 daysDescription: Composite outcome of ICU admission or all-cause death
Measure: Composite outcome of ICU admission or all-cause death Time: Up to 28 daysDescription: Major bleeding as defined by the ISTH Scientific and Standardization Committee (ISTH-SSC) recommendation
Measure: Major bleeding Time: Up to 28 daysDescription: Red Blood Cell transfusion (greater than or equal to 1 unit)
Measure: Number of participants who received red blood cell transfusion Time: Up to 28 daysDescription: Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate
Measure: Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate. Time: Up to 28 daysDescription: Hospital-free days alive up to day 28
Measure: Number of hospital-free days alive up to day 28 Time: Up to 28 daysDescription: ICU-free days alive up to day 28
Measure: Number of ICU-free days alive up to day 28 Time: Up to 28 daysDescription: Ventilator-free days alive up to day 28
Measure: Number of ventilator-free days alive up to day 28 Time: Up to 28 daysDescription: Venous thromboembolism
Measure: Number of participants with venous thromboembolism Time: Up to 28 daysDescription: Arterial thromboembolism
Measure: Number of participants with arterial thromboembolism Time: Up to 28 daysDescription: Heparin induced thrombocytopenia
Measure: Number of participants with heparin induced thrombocytopenia Time: Up to 28 daysDescription: D-dimer
Measure: Changes in D-dimer up to day 3 Time: Up to day 3Randomized, controlled study conducted in hospitalized patients with severe COViD-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation. Aim of this study is to assess whether high doses of Low Molecular Weight Heparin (LMWH) (ie. Enoxaparin 70 IU/kg twice daily) compared to standard prophylactic dose (ie, Enoxaparin 4000 IU once day) are: 1. More effective to prevent clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first, during hospital stay: 1. Death 2. Acute Myocardial Infarction [AMI] 3. Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] 4. Need for either non-invasive - Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) - or invasive mechanical ventilation for patients who are in standard oxygen therapy by delivery interfaces at randomisation 5. Need for invasive mechanical ventilation for patients who are in non-invasive mechanical ventilation at randomisation 2. Similar in terms of major bleeding risk during hospital stay
Description: Death Acute Myocardial Infarction [AMI] Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] Need for either non-invasive - Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) - or invasive mechanical ventilation for patients, who are in standard oxygen therapy by delivery interfaces at randomisation Need for invasive mechanical ventilation for patients, who are in non-invasive mechanical ventilation at randomisation
Measure: Clinical worsening, defined as the occurrence of at least one of the following events, whichever comes first: Time: through study completion, up to 30 daysDescription: Death Acute Myocardial Infarction [AMI] Objectively confirmed, symptomatic arterial or venous thromboembolism [TE] Need for either non-invasive - Continuous Positive Airway Pressure (Cpap) or Non-Invasive Ventilation (NIV) - or invasive mechanical ventilation for patients, who are in standard oxygen therapy by delivery interfaces at randomisation Need for invasive mechanical ventilation for patients, who are in non-invasive mechanical ventilation at randomisation Improvement of laboratory parameters of disease severity, including: D-dimer level Plasma fibrinogen levels Mean Platelet Volume Lymphocyte/Neutrophil ratio IL-6 plasma levels
Measure: Any of the following events occurring within the hospital stay Time: through study completion, up to 30 daysDescription: Information about patients' status will be sought in those who are discharged before 30 days on Day 30 from randomisation.
Measure: Mortality at 30 days Time: 30 daysTo determine whether the coagulopathy associated with COVID-19 infection is driven by overactivation of the renin angiotensin system (RAS)
Description: Mean change from baseline D-dimer at day 8 following administration of TRV027 or placebo.
Measure: Coagulopathy associated with COVID-19 Time: Day 1 and Day 8Description: Absolute D-Dimer - (Fibrin Equivalent units)
Measure: Markers of dysregulation of coagulation system Time: Day 1 and Day 8Description: platelet count (E9 /L)
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: aPTT (Activated Partial Thromboplastin time) - seconds
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: INR - (calculated as a ratio from aPTT)
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: fibrinogen (g/L)
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: Ferritin Ug/mL
Measure: Markers of dysregulation of coagulation system Time: Day 1, 3, Day 5 and Day 8Description: Plasma Renin Mass and activity (ng/ml/h)
Measure: Markers of dysregulation of RAS Time: Day 3, Day 5 and Day 8Description: Total bilirubin (umol/L)
Measure: Markers of Haemolysis/inflammation Time: Day 1, 3, Day 5 and Day 8Description: LDH u/L
Measure: Markers of Haemolysis/Inflammation Time: Day 3, Day 5 and Day 8Description: Haptoglobin g/L
Measure: Markers of Haemolysis/inflammation Time: Day 1, 3, Day 5 and Day 8Description: Pro-calcitonin ug/L
Measure: Markers of Inflammation (bacterial sepsis) Time: day 1, 3, 5 and 8Description: Creatinine (umol/L)
Measure: Markers of organ dysregulation - kidney Time: Day 1, 3, Day 5 and Day 8Description: BNP (B-type natriuetic Peptide) ng/L
Measure: Markers of dysregulation of cardiovascular system Time: Day 1, 3, Day 5 and Day 8Description: Troponin ng/L
Measure: Markers of dysregulation of cardiovascular system Time: Day 1, 3, Day 5 and Day 8Description: glucose mmol/L
Measure: marker of dysregulation of endocrine system Time: Day 1, 3, Day 5 and Day 8The primary aim of this study is to determine whether Camostat mesylate reduces SARS-COV-2 associated coagulopathy. Additional aims are to determine the effect of Camostat mesylate on SARS-COV-2 associated myocardial injury, to assess duration of hypoxia or intubation, to evaluate the length of intensive care unit and hospital stay, and assess mortality rates.
Description: The sum percent change in D-Dimer over 7 days will be compared to day 1
Measure: Percent change in plasma D-Dimer Time: 7 daysDescription: The first assessment on mortality and complications will be carried out 3 months after the start of the study.
Measure: Overall Safety and adverse event Time: 3 monthsDescription: Percent change in fibrinogen over 7 days compared to day 1
Measure: Change in plasma Fibrinogen levels Time: 7 daysDescription: Percent change in troponin over 7 days compared to day 1
Measure: Change in plasma troponin Time: 7 daysDescription: New onset cardiomyopathy defined by a reduction of EF by greater than 10% or less than 45% will be measured
Measure: New onset cardiomyopathy Time: 7 daysDescription: Days with hypoxia (Room Air O2 Sat<93%) or days intubated
Measure: Duration of intubation Time: 7 daysDescription: The number of days in the intensive care unit
Measure: Length of stay in the intensive care unit Time: 28 daysDescription: The number of days since admission to discharge
Measure: Time to discharge from hospital Time: 30 daysDescription: The ocurrence of major adverse cardiovascular events (MACE): MI, stroke, CHF, PCI, death from cardiovascular disease will be studied.
Measure: Occurrence of major adverse cardiovascular events Time: 7 daysPublished papers evaluating coagulopathy on COVID-19 patients indicate a higher incidence of thromboembolic events, sometimes, as high as 20%. Such events increase ICU admissions and are associated with death. Considering the importance of thromboembolic events concurring to deteriorate clinical state, we propose to conduct a parallel pragmatic open-label randomized controlled trial to determine the effect of therapeutic anticoagulation compared to standard care in hospitalized patients with COVID-19 and with low oxygen saturation.
Description: Composite outcome of ICU admission (yes/no), non-invasive positive pressure ventilation (yes/no), invasive mechanical ventilation (yes/no), or all-cause death (yes/no) up to 28 days.
Measure: Composite main outcome Time: up to 28 daysDescription: All-cause death
Measure: All-cause death Time: 28 daysDescription: Composite outcome of ICU admission or all-cause death
Measure: Composite outcome of ICU admission or all-cause death Time: 28 daysDescription: Major bleeding
Measure: Major bleeding Time: 28 daysDescription: Red Blood Cell transfusion (greater than or equal to 1 unit)
Measure: Number of participants who received red blood cell transfusion Time: 28 daysDescription: Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate
Measure: Number of participants with transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipitate and/or fibrinogen concentrate. Time: 28 daysDescription: Hospital-free days alive up to day 28
Measure: Number of hospital-free days alive up to day 28 Time: 28 daysDescription: ICU-free days alive up to day 28
Measure: Number of ICU-free days alive up to day 28 Time: 28 daysDescription: Ventilator-free days alive up to day 28
Measure: Number of ventilator-free days alive up to day 28 Time: 28 daysDescription: Venous thromboembolism
Measure: Number of participants with venous thromboembolism Time: 28 daysDescription: Arterial thromboembolism
Measure: Number of participants with arterial thromboembolism Time: 28 daysDescription: Heparin induced thrombocytopenia
Measure: Number of participants with heparin induced thrombocytopenia Time: 28 daysThis study will study the potential utility of the Quantra QPlus System in patients inflicted with COVID-19 disease.
Description: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: Within 24 hours of admission to the hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: 48 to 72 hours after transfer to ICUDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Time results Time: 1 to 24 hours prior to discharge from hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: Upon arrival at hospitalDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: 48 to 72 hours after transfer to ICUDescription: Coagulation function assessed by the Quantra
Measure: Quantra Clot Stiffness results Time: 1 to 24 hours prior to discharge from hospitalThe study will follow COVID-19 patients who required intensive care after 3-6 months and one year after discharge from the ICU with functional level as well as organ function to assess recovery after COVID-19. Blood and urine will be collected for biobanking.
Description: Death
Measure: Mortality Time: Within 90 days after admission to ICU.Description: Death
Measure: Mortality Time: Within 1 year after admission to ICU.Description: Return of renal function measured as CKD stage.
Measure: Renal recovery Time: At follow-up three to six months after ICU discharge.Description: Return of renal function measured as CKD stage.
Measure: Renal recovery Time: At follow-up one year after ICU discharge.Description: Respiratory function as assessed by a clinician
Measure: Respiratory recovery Time: Three to six months from discharge from ICUDescription: 6 min walk test
Measure: Working capacity Time: Three to six months from discharge from ICUDescription: Quality of Life assessed using the 36-item short form survey by RAND.
Measure: Quality of life score Time: Three to six months from discharge from ICUDescription: Cognitive screening using the Montreal Cognitive Assessment.
Measure: Cognitive recovery Time: Three to six months from discharge from ICUDescription: Screening for frailty using the Clinical Frailty Scale-9.
Measure: Frailty Time: Three to six months from discharge from ICUDescription: Screening of functional level for Activities of Daily Life using the 5-level EQ-5D.
Measure: Activities of Daily Life Time: Three to six months from discharge from ICUDescription: Screening for anxiety using the Generalised Anxiety Disorder 7-item scale.
Measure: Anxiety Time: Three to six months from discharge from ICUDescription: Screening for depression using the Patient Health Questionnaire 9.
Measure: Depression Time: Three to six months from discharge from ICUDescription: Neurological function as assessed by a clinician
Measure: Neurological recovery Time: Three to six months from discharge from ICU